Literature DB >> 30670830

Approvals in 2018: a histology-agnostic new molecular entity, novel end points and real-time review.

Gideon M Blumenthal1, Richard Pazdur2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30670830     DOI： 10.1038/s41571-019-0170-z

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  8 in total

1.  An Analysis of Recent FDA Oncology Scientific Publications.

Authors:  Julie A Schneider; Andrew C Miklos; James Onken; Yutao Gong; Anna Maria Calcagno; Gideon M Blumenthal; Richard Aragon; Richard Pazdur
Journal:  Oncologist       Date:  2019-11-26

2.  Right to Try Requests and Oncologists' Gatekeeping Obligations.

Authors:  Holly Fernandez Lynch; Ameet Sarpatwari; Robert H Vonderheide; Patricia J Zettler
Journal:  J Clin Oncol       Date:  2019-10-15       Impact factor: 44.544

Review 3.  Targeted Therapy in Early Stage Non-small Cell Lung Cancer.

Authors:  Si-Yang Liu; Si-Yang Maggie Liu; Wen-Zhao Zhong; Yi-Long Wu
Journal:  Curr Treat Options Oncol       Date:  2022-07-25

Review 4.  ＜Editors' Choice＞ How to improve outcomes of elderly patients with acute myeloid leukemia: era of excitement.

Authors:  Tomoki Naoe
Journal:  Nagoya J Med Sci       Date:  2020-05       Impact factor: 1.131

5.  An innovative diagnostic strategy for the detection of rare molecular targets to select cancer patients for tumor-agnostic treatments.

Authors:  Antonio Marchetti; Alessia Di Lorito; Lara Felicioni; Fiamma Buttitta
Journal:  Oncotarget       Date:  2019-12-10

6.  Anticancer Drugs Approved by the US Food and Drug Administration From 2009 to 2020 According to Their Mechanism of Action.

Authors:  Timothée Olivier; Alyson Haslam; Vinay Prasad
Journal:  JAMA Netw Open       Date:  2021-12-01

7.  Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCO-Friends of Cancer Research Washout Period and Concomitant Medication Work Group.

Authors:  R Donald Harvey; Kathryn F Mileham; Vishal Bhatnagar; Jamie R Brewer; Atiqur Rahman; Cassadie Moravek; Andrew S Kennedy; Elizabeth A Ness; E Claire Dees; S Percy Ivy; Scot W Ebbinghaus; Caroline Schenkel; Thomas S Uldrick
Journal:  Clin Cancer Res       Date:  2021-02-09       Impact factor: 13.801

8.  PTEN Expression as a Complementary Biomarker for Mismatch Repair Testing in Breast Cancer.

Authors:  Gianluca Lopez; Marianna Noale; Chiara Corti; Gabriella Gaudioso; Elham Sajjadi; Konstantinos Venetis; Donatella Gambini; Letterio Runza; Jole Costanza; Chiara Pesenti; Francesco Grossi; Stefania Maggi; Stefano Ferrero; Silvano Bosari; Nicola Fusco
Journal:  Int J Mol Sci       Date:  2020-02-21       Impact factor: 5.923
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.